RxDoctor Payments Data

Bryan Bonder, MD

Hematology & Oncology · Cleveland, OHNPI 1063705150

Payments from drug & device makers

$307in general payments, 2019–2025

Across 14 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$92
  • Incyte Corporation$53
  • Astellas Pharma US Inc$44
  • Karyopharm Therapeutics Inc.$22
  • Taiho Oncology, Inc.$19
  • Takeda Pharmaceuticals U.S.A., Inc.$15
  • plus $63 from 5 others

What the payments were for

  • Food & beverage$307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$307 in reported general payments places this provider in the 15th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$63,795
Medicare patients
228
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib36$423,998
EliquisApixaban74$56,612
Abiraterone Acetate32$54,379
XareltoRivaroxaban24$23,093
Imatinib Mesylate26$3,276
Mycophenolate Mofetil11$1,923
Lacosamide15$958
Ondansetron Hcl12$761
Prochlorperazine Maleate33$598
Hydroxyurea48$525
Dexamethasone22$477
Potassium Chloride34$398
Acyclovir28$392
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$261
Prednisone74$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Acyclovir$11$39228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →